Department of Pain Management, West China Hospital, Sichuan University.
Department of Anesthesiology, Sichuan Cancer Center, Sichuan Cancer Hospital & Institute, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China.
Clin J Pain. 2018 Nov;34(11):1025-1031. doi: 10.1097/AJP.0000000000000623.
This study evaluated the analgesic efficacy and emotional response to intravenous lidocaine infusion compared with placebo in patients with postherpetic neuralgia (PHN).
In this randomized, double-blinded study, patients with PHN received 5 mg/kg intravenous lidocaine infusion or placebo. The primary outcome was pain measured by Visual Analogue Scale, Von Frey, and area of allodynia. Moreover, emotional status of anxiety and depression were evaluated by Self-rating Anxiety Scale (SAS) and Self-rating Depression Scale (SDS). Quality of life was assessed by Short Form Health Survey 36.
In total, 197 patients were enrolled and eligible data were collected from 183 of those patients. The Visual Analogue Scale scores were reduced to a minimum at 2 weeks (2.74, 2.99) after infusion, but no significant difference was found between the lidocaine and placebo groups. Similar changes were also found in mechanical pain threshold and area of allodynia. However, the lidocaine group was associated with a statistically significant reduction in consumption of analgesics with a relative risk of 6.2 (95% confidence interval [CI], 2.24-17.16). Lidocaine infusion also significantly improved the anxiety and depression status; the values of mean change in anxiety and depression were 3.89 (95% CI, 1.43-6.35) and 4.3 (95% CI, 0.63-7.98), respectively, at 2 weeks. Moreover, improvement was exhibited in Short Form Health Survey 36 health status, with the mean change of 49.81 (95% CI, 28.17-71.46) at 1 week, in particular scores on vitality, physical and emotional role functioning, and mental health.
The analgesic response of 5 mg/kg lidocaine intravenous infusion is comparable to placebo in patients with PHN, but intravenous lidocaine infusion significantly reduced total analgesic consumption, and improved the overall emotional and health status.
本研究旨在评估与安慰剂相比,静脉注射利多卡因在带状疱疹后神经痛(PHN)患者中的镇痛效果和情绪反应。
在这项随机、双盲研究中,PHN 患者接受 5mg/kg 静脉注射利多卡因或安慰剂。主要结局是通过视觉模拟量表、冯弗雷和感觉异常面积来测量疼痛。此外,通过自评焦虑量表(SAS)和自评抑郁量表(SDS)评估焦虑和抑郁情绪状态。通过健康调查简表 36(SF-36)评估生活质量。
共纳入 197 例患者,其中 183 例患者纳入符合条件的数据。输注后 2 周时,视觉模拟量表评分降至最低(2.74,2.99),但利多卡因组和安慰剂组之间无显著差异。机械痛阈和感觉异常面积也有类似的变化。然而,与安慰剂组相比,利多卡因组的镇痛药消耗量显著降低,相对风险为 6.2(95%置信区间[CI],2.24-17.16)。利多卡因输注还显著改善了焦虑和抑郁状态;焦虑和抑郁的平均变化值分别为 3.89(95%CI,1.43-6.35)和 4.3(95%CI,0.63-7.98),均在 2 周时。此外,SF-36 健康状况也有所改善,在 1 周时平均变化为 49.81(95%CI,28.17-71.46),特别是活力、身体和情绪角色功能以及心理健康方面的评分。
5mg/kg 利多卡因静脉输注在 PHN 患者中的镇痛效果与安慰剂相当,但静脉注射利多卡因可显著减少总镇痛药用量,并改善整体情绪和健康状况。